Advanced search
Publication Cover
Expert Opinion on Biological Therapy Volume 16, 2016 - Issue 7
Submit an article Journal homepage
1,368
Views
3
CrossRef citations to date
0
Altmetric
Editorial

Combined cell-gene therapy for lung cancer: rationale, challenges and prospects

Ricky M. ThakrarLungs for Living Research Centre, UCL Respiratory, University College London, Rayne Institute, London, UK;Department of Thoracic Medicine, University College London Hospital, London, UKCorrespondence[email protected]
,
Elizabeth K. SageLungs for Living Research Centre, UCL Respiratory, University College London, Rayne Institute, London, UK
&
Sam M. JanesLungs for Living Research Centre, UCL Respiratory, University College London, Rayne Institute, London, UK;Department of Thoracic Medicine, University College London Hospital, London, UK
Pages 853-857 | Received 22 Mar 2016, Accepted 06 May 2016, Published online: 03 Jun 2016

References

  • Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90. doi:10.3322/caac.20107.
  • Non-small Cell Lung Cancer Collaborative. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small cell lung cancer collaborative group. BMJ. 1995;311:899–909.
  • Johnson DH, Schiller JH, Bunn PA Jr. Recent clinical advances in lung cancer management. J Clin Oncol. 2014;32(10):973–982. doi:10.1200/JCO.2013.54.6911.
  • Loebinger MR, Janes SM. Stem cells as vectors for antitumour therapy. Thorax. 2010;65(4):362–369. doi:10.1136/thx.2009.128025.
  • Stuckey DW, Shah K. TRAIL on trial: preclinical advances in cancer therapy. Trends Mol Med. 2013;19(11):685–694. doi:10.1016/j.molmed.2013.08.007
  • Loebinger MR, Eddaoudi A, Davies D, et al. Mesenchymal stem cell delivery of TRAIL can eliminate metastatic cancer. Cancer Res. 2014;69(10):4134–4142. doi:10.1158/0008-5472.CAN-08-4698.
  • Hoogduijn MJ, Popp F, Verbeek R, et al. The immunomodulatory properties of mesenchymal stem cells and their use for immunotherapy. Int Immunopharmacol. 2010;10(12):1496–1500. doi:10.1016/j.intimp.2010.06.022.
  • Lourenco S, Teixeira VH, Kalber T, et al. Macrophage migration inhibitory factor-CXCR4 is the dominant chemotactic axis in human mesenchymal stem cell recruitment to tumors. J Immunol. 2015;194(7):3463–3474. doi:10.4049/jimmunol.1402705.
  • Stuckey DW, Shah K. Stem cell-based therapies for cancer treatment: separating hope from hype. Nat Rev Cancer. 2014;14(10):683–691. doi:10.1038/nrc3798
  • Heathman TRJ, Nienow AW, McCall MJ, et al. The translation of cell-based therapies: clinical landscape and manufacturing challenges. Regen Med. 2015;10(1):49–64. doi:10.2217/rme.14.73.
  • Niess H, Von Einem JC, Thomas MN, et al. Treatment of advanced gastrointestinal tumors with genetically modified autologous mesenchymal stromal cells (TREAT-ME1): study protocol of a phase I/II clinical trial. BMC Cancer. 2015;15(1):1–13. doi:10.1186/s12885-015-1584-3.
  • Jung S, Panchalingam KM, Wuerth RD, et al. Large-scale production of human mesenchymal stem cells for clinical applications. Biotechnol Appl Biochem. 2012;59(2):106–120. doi:10.1002/bab.1006.
  • Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. Int Soc Cell Ther Position Statement. Cytotherapy. 2006;8(4):315–317.
  • Prockop DJ, Brenner M, Fibbe WE, et al. Defining the risks of mesenchymal stromal cell therapy. Cytotherapy. 2010;12(5):576–578. doi:10.3109/14653249.2010.507330.
  • Galipeau J, Krampera M, Barrett J, et al. International society for cellular therapy perspective on immune functional assays for mesenchymal stromal cells as potency release criterion for advanced phase clinical trials. Cytotherapy. 2015;18(2):151–159. doi:10.1016/j.jcyt.2015.11.008.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.